文献速递系统性红斑狼疮其他结缔组织病

ANK1与EPB41罕见变异增加糖皮质激素性股骨头坏死风险

ANK1 and EPB41 Variants and The Risk of Glucocorticoid-Induced Osteonecrosis.
PubMed 文献 · Arthritis Rheumatol · 2026-05-03

该研究对174例接受糖皮质激素治疗的系统性红斑狼疮(SLE)患者行全外显子测序,在83例股骨头坏死(SONFH)患者中检出9例(10.8%)携带ANK1或EPB41罕见变异,而91例无SONFH对照中为0例。这些变异经另一246例非SLE SONFH队列验证检出10例(4.1%),功能分析显示变异导致红细胞膜功能障碍,提示其作为SONFH新型遗传风险因素。

要点

  • 携带ANK1或EPB41罕见变异与SONFH风险显著相关,调整后OR分别为11.3和32.3(P<0.05)。
  • 变异导致红细胞ANK1表达降低、形态异常及低渗溶血增加,损害红细胞膜完整性。
  • 在非SLE的SONFH验证队列中,10/246例(4.1%)检出这些变异。

核心结论

  • ANK1和EPB41罕见变异是SONFH的新型疾病风险因素,通过损害红细胞膜完整性在糖皮质激素作为第二次打击时加重微循环损伤。

研究设计与样本

  • 在174例接受糖皮质激素治疗的SLE患者中进行SONFH病例对照全外显子测序,并与民族匹配的健康人群比较,另在246例非SLE的SONFH队列中验证。
  • 通过遗传负荷分析和Sanger测序及家系研究确认罕见损害性变异,并对靶变异进行红细胞功能评估。

主要发现

  • 在83例SONFH患者中检出9例(10.8%)携带10个ANK1或EPB41罕见变异,而91例无SONFH对照中为0例(0%)。
  • Firth逻辑回归调整后,ANK1的调整OR为11.3,EPB41的调整OR为32.3,均P<0.05。
  • 在246例非SLE的SONFH验证队列中,10例(4.1%)检出这些变异。
  • 功能分析显示患者红细胞膜功能障碍,表现为ANK1表达降低、形态异常和低渗溶血增加。

临床怎么用

  • 对于接受糖皮质激素治疗的SLE患者,可考虑检测ANK1和EPB41罕见变异以识别SONFH高风险个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Steroid-induced osteonecrosis of the femoral head (SONFH) is a refractory skeletal disorder influenced by genetic and environmental factors. However, conclusive pathogenic genetic evidence remains elusive due to the limited exploration of rare damaging variants. In this study, we aimed to identify rare variants associated with SONFH. METHODS: We conducted whole-exome sequencing in an SONFH case-control study comprising 174 patients with systemic lupus erythematosus (SLE) taking steroids, followed by comparing the cases with an ethnically matched healthy population and validation in an additional SONFH cohort of 246 patients without SLE. Rare damaging variants were identified via genetic burden analysis and confirmed by Sanger sequencing and pedigree studies. The functional assessments of the erythrocytes on target variants were performed. RESULTS: We identified 10 heterozygous ANK1 and EPB41 rare variants in 9 (10.8%) of 83 patients with SONFH compared with 0 of the 91 non-SONFH controls (0%). The burden effect of them remained robust after adjusted analysis (Firth's logistic regression-adjusted odds ratio [aOR]ANK1 11.3; aOREPB41 32.3; both P < 0.05). The variants were detected in 10 of the validated SONFH cohort (4.1%) with 246 non-SLE conditions. Functional analyses revealed that the variants result in membrane dysfunctions in the patients' erythrocytes, characterized by reduced ANK1 expression, abnormal morphology, and increased hypotonic hemolysis. CONCLUSION: These findings suggest that the rare variants in ANK1 and EPB41 are novel SONFH disease risk factors that compromise erythrocyte membrane integrity, exacerbating microcirculatory damage in the presence of glucocorticoid as a second hit.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Chen S, Zhu X, Chen Z, et al. ANK1 and EPB41 Variants and The Risk of Glucocorticoid-Induced Osteonecrosis. Arthritis Rheumatol. 2026. PMID: 41920036. doi:10.1002/art.70153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。